Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ABT-894: Phase II started

ABT began a double-blind, placebo-controlled, dose-ranging Phase II in 275 patients.

Read the full 113 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE